Connect with us

Technology

NUTEX HEALTH REPORTS THIRD QUARTER AND YEAR TO DATE SEPTEMBER 30, 2024 FINANCIAL RESULTS

Published

on

TOTAL REVENUE OF $222.3 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $178.0 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 25%HOSPITAL DIVISION VISITS OF 122,944 FOR THE FIRST NINE MONTHS OF 2024 VS. VISITS OF 102,798 FOR THE SAME PERIOD IN 2023, AN INCREASE OF 20%HOSPITAL DIVISION OPERATING INCOME OF $54.7 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $21.1 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 159%NET CASH FROM OPERATING ACTIVITIES OF $23.1 MILLION FOR THE FIRST NINE MONTHS OF 2024COMPANY CONTINUES ITS FOCUS ON INCREASING CASH FLOW

HOUSTON, Nov. 7, 2024 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in ten states and primary care-centric, risk-bearing physician networks, today announced third quarter 2024 financial results for the three and nine months ended September 30, 2024.

Financial Highlights for the Three Months Ended September 30, 2024:

Total revenue of $78.8 million as compared to total revenue of $62.7 million for the three months ended September 30, 2023, an increase of 26%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 20.7% in 2024 compared to the same period in 2023.Operating income (including the negative impact of a $2.0 million non-cash stock-based compensation expense) for the three months ended September 30, 2024 was $9.7 million, compared to an operating loss of approximately $0.8 million for the three months ended September 30, 2023, representing a $10.5 million improvement quarter over quarter.Net loss attributable to Nutex Health of $8.8 million in the three months ended September 30, 2024 as compared to a net loss attributable to Nutex Health of $5.5 million for the three months ended September 30, 2023. This $8.8 million amount includes a $6.7 million non-cash loss on warrant liability as well as the $2.0 million non-cash stock-based compensation expense noted above.EBITDA attributable to Nutex Health of $4.3 million, as compared to EBITDA attributable to Nutex Health of $1.2 million for the three months ended September 30, 2023.Adjusted EBITDA attributable to Nutex Health of $13.5 million, as compared to Adjusted EBITDA attributable to Nutex Health of $1.3 million for the three months ended September 30, 2023, an increase of 938%.Total visits from the Hospital Division were 41,668 for the third quarter 2024, as compared to 37,443 for the third quarter 2023, an increase of 4,225 or 11.3%. Of this visit growth, mature hospitals increased by 3.8% in 2024 compared to the same period in 2023.

Financial Highlights for the Nine Months Ended September 30, 2024:

Total revenue of $222.3 million as compared to total revenue of $178.0 million for the nine months ended September 30, 2023, an increase of approximately 25%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 13.5% in 2024 compared to 2023.Operating income for the nine months ended September 30, 2024 was $16.4 million compared to an operating loss of $5.6 million for the nine months ended September 30, 2023, representing a $22.0 million improvement year over year.Net loss attributable to Nutex Health of $9.5 million as compared to net loss attributable to Nutex Health of $14.2 million for the nine months ended September 30, 2023. This $9.5 million amount includes non-cash items of $10.2 million (non-cash stock-based compensation expense of $2.0 million, non-cash impairment of assets of $3.9 million, non-cash impairment of goodwill of $3.2 million and $1.1 million non-cash loss on warrant liability) in the first nine months of 2024, while the $14.2 million amount includes non-cash stock-based compensation expense of $2.2 million in the first nine months of 2023.EBITDA attributable to Nutex Health of $19.9 million, as compared to EBITDA attributable to Nutex Health of $5.3 million for the nine months ended September 30, 2023.Adjusted EBITDA attributable to Nutex Health of $30.1 million, as compared to Adjusted EBITDA attributable to Nutex Health of $7.7 million for the nine months ended September 30, 2023, an increase of 290%.Total visits from the Hospital Division were 122,944 for the nine months ended September 30, 2024, as compared to 102,798 for the same period in 2023, an increase of 20,146 or 19.6%. Of this visit growth, mature hospitals increased by 7.7% in the nine months ended September 30, 2024 compared to the same period in 2023.Net cash from operating activities of $23.1 million for the nine months ended September 30, 2024. As of September 30, 2024, the Company had total assets of $438.5 million, including cash and cash equivalents of $46.9 million and long-term debt of $26.8 million.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

“We are pleased to report 25% revenue growth, Adjusted EBITDA attributable to Nutex Health of $13.5 million and a 209% increase in gross profit to $21.9 million in the third quarter ended September 30, 2024, showing our continued focus on top line growth, increasing cash flow as well as improving profitability,” stated Jon Bates, Chief Financial Officer of Nutex Health.

“Nutex Health had another outstanding quarter. The strategic and operational decisions we have made over the last nine months are driving this strong performance, as demonstrated by another quarter of year-over-year growth in revenue, EBITDA and Adjusted EBITDA as well as incremental growth in cash flow. We are confident that our momentum will continue and plan on growing our hospital and population health divisions responsibly as we drive value for our shareholders,” stated Warren Hosseinion, M.D., President of Nutex Health.

“The four de-novo hospitals that we opened in 2023 are ramping up nicely, resulting in strong year-over-year growth in both revenue and patient volume. Volumes and revenue continue to increase among our mature hospitals, both on the outpatient side as well as the inpatient side, which still have excess capacity. Our average payment by insurers of patient claims also increased, a trend we are optimistic will persist as we continue to work the NSA (No Surprises Act) claims through the Independent Dispute Resolution process,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company’s Third Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2024

December 31, 2023

Assets

Current assets:

Cash and cash equivalents

$

46,909,281

$

22,002,056

Accounts receivable

62,745,336

58,624,301

Accounts receivable – related parties

3,602,189

4,152,068

Inventories

2,259,168

3,390,584

Prepaid expenses and other current assets

4,279,360

2,679,394

Total current assets

119,795,334

90,848,403

Property and equipment, net

78,246,467

81,387,649

Operating right-of-use assets

11,442,369

11,853,082

Finance right-of-use assets

198,462,381

176,146,329

Intangible assets, net

15,855,392

20,512,636

Goodwill, net

13,918,719

17,066,263

Other assets

767,942

431,135

Total assets

$

438,488,604

$

398,245,497

Liabilities and Equity

Current liabilities:

Accounts payable

$

10,320,933

$

18,899,196

Accounts payable – related parties

6,342,883

6,382,197

Lines of credit

3,384,517

3,371,676

Current portion of long-term debt

10,499,532

10,808,721

Operating lease liabilities, current portion

2,060,758

1,579,987

Finance lease liabilities, current portion

5,261,458

4,315,979

Accrued expenses and other current liabilities

29,688,665

12,955,296

Total current liabilities

67,558,746

58,313,052

Long-term debt, net

26,801,811

26,314,733

Warrant liability

5,715,143

Operating lease liabilities, net

14,307,320

15,479,639

Finance lease liabilities, net

240,924,194

213,886,213

Deferred tax liabilities

3,402,965

5,145,754

Total liabilities

358,710,179

319,139,391

Commitments and contingencies

Equity:

Common stock, $0.001 par value; 950,000,000 shares authorized; 5,215,709 and 4,511,199
shares issued and outstanding as of September 30, 2024 and December 31, 2023,
respectively

5,216

4,511

Additional paid-in capital

479,024,452

470,521,218

Accumulated deficit

(418,588,975)

(409,072,539)

Nutex Health Inc. equity

60,440,693

61,453,190

Noncontrolling interests

19,337,732

17,652,916

Total equity

79,778,425

79,106,106

Total liabilities and equity

$

438,488,604

$

398,245,497

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

Three Months Ended September 30, 

Nine Months Ended September 30, 

2024

2023

2024

2023

Revenue:

Hospital division

$

71,732,529

$

54,585,263

$

199,366,776

$

155,485,230

Population health management division

7,062,340

8,137,709

22,964,141

22,491,613

Total revenue

78,794,869

62,722,972

222,330,917

177,976,843

Operating costs and expenses:

Payroll and benefits

29,848,083

28,873,144

85,249,302

79,570,519

Contract services

11,657,010

9,035,650

32,481,686

27,972,854

Medical supplies

3,982,598

3,460,130

12,892,904

10,748,214

Depreciation and amortization

4,972,478

4,745,941

13,691,484

12,908,848

Other

6,417,886

9,541,894

23,380,318

25,215,549

Total operating costs and expenses

56,878,055

55,656,759

167,695,694

156,415,984

Gross profit

21,916,814

7,066,213

54,635,223

21,560,859

Corporate and other costs:

Facilities closing costs

217,266

Acquisition costs

43,464

43,464

Stock-based compensation expense

1,963,518

49,167

1,951,444

2,198,812

Impairment of assets

425,221

3,898,856

Impairment of goodwill

3,197,391

General and administrative expenses

9,865,330

7,794,808

29,176,130

24,730,168

Total corporate and other costs

12,254,069

7,887,439

38,223,821

27,189,710

Operating income (loss)

9,662,745

(821,226)

16,411,402

(5,628,851)

Interest expense, net

5,381,040

4,098,179

14,879,934

12,081,316

Loss on warrant liability

6,733,552

1,072,709

Other (income) expense

128,645

(53,206)

(712,049)

70,721

Income (loss) before taxes

(2,580,492)

(4,866,199)

1,170,808

(17,780,888)

Income tax expense (benefit)

4,584,518

(342,259)

5,868,075

(2,068,530)

Net loss

(7,165,010)

(4,523,940)

(4,697,267)

(15,712,358)

Less: net income (loss) attributable to
noncontrolling interests

1,623,303

1,018,451

4,819,169

(1,543,641)

Net loss attributable to Nutex Health Inc.

$

(8,788,313)

$

(5,542,391)

$

(9,516,436)

$

(14,168,717)

Loss per common share:

Basic

$

(1.72)

$

(1.25)

$

(1.91)

$

(3.23)

Diluted

$

(1.72)

$

(1.25)

$

(1.91)

$

(3.23)

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Nine Months Ended September 30, 

2024

2023

Cash flows from operating activities:

Net income (loss)

$

(4,697,267)

$

(15,712,358)

Adjustments to reconcile net loss to net cash from operating activities:

Depreciation and amortization

13,691,484

12,908,848

Loss on warrant liability

1,072,709

Impairment of goodwill

3,197,391

Impairment of assets

3,898,856

Derecognition of goodwill

453,017

Stock-based compensation expense

1,951,444

2,198,812

Deferred tax benefit

(1,742,789)

(2,068,530)

Debt accretion expense

804,760

1,251,867

Loss on lease termination

58,210

Non-cash lease expense (income)

(280,835)

89,338

Changes in operating assets and liabilities, net of the effects of acquisitions:

Accounts receivable

(4,253,034)

4,444,706

Accounts receivable – related party

549,879

(949,408)

Inventories

1,131,416

850,569

Prepaid expenses and other current assets

(1,360,721)

(3,771,946)

Accounts payable

(7,975,067)

(6,015,250)

Accounts payable – related party

(39,314)

2,228,527

Accrued expenses and other current liabilities

16,698,416

7,519,285

Net cash from operating activities

23,100,345

3,032,670

Cash flows from investing activities:

Acquisitions of property and equipment

(1,908,651)

(10,322,487)

Cash related to sale of business

(361,325)

Payments for acquisitions of businesses, net of cash acquired

(743,837)

Cash related to deconsolidation of Real Estate Entities

(1,039,157)

Net cash from investing activities

(2,269,976)

(12,105,481)

Cash flows from financing activities:

Proceeds from lines of credit

1,132,168

2,340,911

Proceeds from notes payable

7,014,999

16,952,905

Proceeds from convertible notes

891,000

Repayments of lines of credit

(1,119,327)

(1,592,714)

Repayments of notes payable

(8,332,482)

(10,557,758)

Repayments of finance leases

(1,923,687)

(2,704,082)

Proceeds from common stock issuance, net issuance costs

9,202,500

Proceeds from exercise of warrants

801,000

Members’ contributions

960,913

649,550

Members’ distributions

(3,659,228)

(4,335,532)

Net cash from financing activities

4,076,856

1,644,280

Net change in cash and cash equivalents

24,907,225

(7,428,531)

Cash and cash equivalents – beginning of the period

22,002,056

34,255,264

Cash and cash equivalents – end of the period

$

46,909,281

$

26,826,733

 

Non-GAAP Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.

We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for an allocation to noncontrolling interests, (gain)/loss on warrant liability, stock-based compensation, certain defined items of expense, and any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. EBITDA and Adjusted EBITDA are not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.

Three Months Ended September 30, 

Nine Months Ended September 30, 

2024

2023

2024

2023

Reconciliation of net loss attributable to Nutex Health
Inc. to Adjusted EBITDA:

Net loss attributable to Nutex Health Inc.

$

(8,788,313)

$

(5,542,391)

$

(9,516,436)

$

(14,168,717)

Depreciation and amortization

4,972,478

4,745,941

13,691,484

12,908,848

Interest expense, net

5,381,040

4,098,179

14,879,934

12,081,316

Income tax expense (benefit)

4,584,518

(342,259)

5,868,075

(2,068,530)

Allocation to noncontrolling interests

(1,808,422)

(1,772,908)

(4,980,424)

(3,500,873)

EBITDA attributable to Nutex Health Inc.

4,341,301

1,186,562

19,942,633

5,252,044

Facilities closing costs

217,266

Loss on warrant liability

6,733,552

1,072,709

Impairment of assets

425,221

3,898,856

Impairment of goodwill

3,197,391

Acquisition costs

43,464

43,464

Stock-based compensation expense

1,963,518

49,167

1,951,444

2,198,812

Adjusted EBITDA attributable to Nutex Health Inc.

$

13,463,592

$

1,279,193

$

30,063,033

$

7,711,586

 

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 22 facilities in ten states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 and in the Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 and June 30, 2024 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-third-quarter-and-year-to-date-september-30-2024-financial-results-302299409.html

SOURCE Nutex Health, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

How the Top 10% of CTOs Drive Meaningful Business Growth

Published

on

By

Only a shocking 10% of CTOs will drive value for their organizations, according to a recent Forester prediction. By understanding how the top 10% of CTOs have reshaped their role, this article discusses how aspiring trailblazers can shift their perspectives and priorities to join the elite ranks of tech leaders.

SAINT PAUL, Minn., Nov. 7, 2024 /PRNewswire-PRWeb/ — Forrester experts have made a prediction that should be a resounding wake-up call for tech leaders: only 10% of CTOs will actually drive business growth. For the other 90%, the risk is clear—CTOs who fail to demonstrate their value will quickly be replaced by ones who can.

Elite tech leaders serve as thought leaders and pioneers within their own field. As such, the top 10% of CTOs today focus on claiming competitive advantages through the use of emerging technologies. – Inkit CEO Michael McCarthy

What exactly defines this new breed of tech leader, and what are these elite CTOs doing differently to drive growth? Here are the three essential practices that differentiate the good from the great CTOs today.

They Focus on Scale

Successful CTOs align their strategies with overall business goals, using automation and integrated technologies to scale other departments. By implementing centralized tools that standardize data, unify analytics, and automate tedious processes like lead scoring, follow-ups, relationship management, and contract management, elite CTOs are empowering RevOps, sales, and marketing teams to optimize every step of the sales funnel, reach more potential leads, and close deals faster.

However, for the top 10% of CTOs, successfully driving growth is not a solo endeavor. They know that leadership buy-in determines future outcomes for any digital transformation initiative.

They Work Closely with Other CxOs

According to Gartner, by co-leading initiatives with their fellow CxOs, CTOs are twice as likely to meet or exceed expected ROIs for digital technology investments. This involves creating cross-department teams that share responsibilities for technology rollouts, pool resources, and lend vertical-specific knowledge to ensure the most efficient and valuable outcomes. Co-leadership structured engagements also have the potential to uncover new areas for improvement and enhance organizational collaboration and culture.

While working with CxOs unlocks new opportunities within these non-tech domains, elite tech leaders serve as thought leaders and pioneers within their own field. As such, the top 10% of CTOs today focus on claiming competitive advantages through the use of emerging technologies.

If There’s New Tech, They’re Already Using It

Another prediction from the Forrester report indicates that enterprise AI initiatives will boost productivity and creative problem-solving by 50% in 2024. Similarly, Generative AI has become a popular tool to simplify user interfaces and serve as a digital assistant within complicated tools. CTOs are hurrying to adopt AI before their competitors, and businesses today are quick to announce their implementation of next-gen technologies that claim to improve their products with new, dazzling features—but the top 10% of CTOs have assessed these new technologies well before the rest.

Document generation (i.e., DocGen) and digital signatures are another technology on the radar for many top CTOs. Regarded as a vital tool for automating digital workflows, DocGen empowers organizations to create, share, sign, and retain documents at scale. DocGen tools also help CTOs to automatically meet compliance requirements for security, data privacy, and retention policies across the entire organization with minimal training required.

Finally, for CTOs in retail, finance, cryptocurrency, and logistics, blockchain and Internet of Things (IoT) technology allow for secure, autonomous machine-to-machine transactions that reduce operational complexity and open new avenues for innovation in smart automation.

Join the Elite CTOs Driving Business Growth

Top CTOs drive growth by strategically aligning advanced technologies with business goals through cross-functional teamwork. By evaluating emerging technologies like Generative AI, document generation, automation, and more, the top 10% of CTOs are successfully accelerating the pace of growth, innovation, and collaboration for their organizations.

About Inkit

Inkit is the only Secure Document Generation (SDG) software that allows users to generate, sign, and retain documents in total privacy. Scale your workflows using our DocGen automation solution to create documents and forms using custom templates and data sources with our API. Elevate the security of your legally-binding documents with digital signatures. Protect agreements with advanced encryption and authenticity certificates to streamline processes and ensure peace of mind. Get the privacy and automation your team needs to optimize records management and compliance. Create disappearing documents that automatically expire based on predesignated parameters. Connect seamlessly with your favorite apps to generate Microsoft Word, PowerPoint, Excel, PDF, and HTML documents. Experience an all-inclusive solution for ultimate file control and security. Inkit is privately owned and headquartered in St. Paul, Minnesota, with offices in San Juan, Puerto Rico, and Washington, D.C.

Media Contact

Patrick Lethert, Inkit, 1 8008995773, patrick@inkit.com, https://www.inkit.com

LinkedIn

View original content to download multimedia:https://www.prweb.com/releases/how-the-top-10-of-ctos-drive-meaningful-business-growth-302298321.html

SOURCE Inkit

Continue Reading

Technology

LG Energy Solution to Supply Next-Generation 4695 Cylindrical Batteries to Rivian

Published

on

By

Supply agreement will last over five years and total 67GWh.4695 cells, offering a long range and high safety, will be produced in the U.S.Batteries will power Rivian’s R2 model for the North American market.

SEOUL, South Korea, Nov. 7, 2024 /PRNewswire/ — LG Energy Solution (KRX: 373220) today announced that LG Energy Solution Arizona, a fully owned subsidiary of LG Energy Solution, has signed a supply agreement with Rivian, a U.S.-based automotive manufacturer.

Under the agreement, LG Energy Solution will provide Rivian with its advanced 4695 cylindrical batteries for over five years, totaling 67GWh.

With a diameter of 46mm and height of 95mm, the next-generation 4695 cylindrical battery is recognized for offering both a long range and high safety. It features over six times the capacity of the existing 2170 cylindrical batteries. Its larger size enables higher energy density, improved space efficiency, and enhanced safety, which is attracting industry-wide attention.

Within the first year of production, the batteries will be eventually manufactured at LG Energy Solution’s stand-alone plant in Arizona, and delivered to Rivian’s facility in Normal, Illinois, for use in the R2 model for the North American market.

LG Energy Solution has been advancing its cylindrical battery technology over the past 20 years, supported by its extensive manufacturing experience and broad patent portfolio.

The supply agreement with Rivian is expected to further strengthen LG Energy Solution’s presence in the U.S. market and its plans to actively respond to the IRA by developing and supplying competitive battery cells in a timely manner while expanding into new markets.

Given the strong interest from automakers in its 46-series cylindrical batteries, LG Energy Solution also expects to extend its leadership in this growing sector.

“Due to the dynamic nature of the current EV market, an increasing number of global automakers are demonstrating a strong preference for a diverse range of battery form factors,” said David Kim, CEO of LG Energy Solution. “This large-scale order from Rivian for 4695 batteries marks a key milestone for LG Energy Solution in expanding its client base within the cylindrical battery segment.”

About LG Energy Solution

LG Energy Solution (KRX: 373220), a split-off from LG Chem, is a leading global manufacturer of lithium-ion batteries for electric vehicles, mobility, IT, and energy storage systems. With 30 years of experience in revolutionary battery technology and extensive research and development (R&D), the company is the top battery-related patent holder in the world with over 58,000 patents. Its robust global network, which spans North America, Europe, and Asia, includes battery manufacturing facilities established through joint ventures with major automakers. Committed to building sustainable battery ecosystem, LG Energy Solution aims to achieve carbon neutrality across its value chain by 2050, while embodying the value of shared growth and promoting diverse and inclusive corporate culture. To learn more about LG Energy Solution’s ideas and innovations, visit https://news.lgensol.com.

View original content:https://www.prnewswire.com/news-releases/lg-energy-solution-to-supply-next-generation-4695-cylindrical-batteries-to-rivian-302299455.html

SOURCE LG Energy Solution

Continue Reading

Technology

PayrollOrg’s Chapter Leadership Summit to Equip Payroll Chapter Leaders with Tools for Success

Published

on

By

LAS VEGAS, Nov. 7, 2024 /PRNewswire/ — PayrollOrg (PAYO) will provide local chapter leaders with the essential tools and guidance they need to ensure the ongoing success of their chapters at the Chapter Leadership Summit, November 7 – 8 in Las Vegas, Nevada.

“Supporting our chapter leaders is crucial to the growth and sustainability of local chapters,” said Dan Maddux, executive director of PayrollOrg. “The Chapter Leadership Summit is designed to not only provide practical tools and strategies but also foster a strong network of motivated leaders who can inspire their teams and communities.”

Participants will have the unique opportunity to connect with fellow leaders, exchange ideas, and develop strategies to motivate their chapter members. Tailored educational sessions will offer specialized training on critical topics such as fiscal responsibility, general chapter operations, and event planning. These sessions will be led by guest speakers with expertise in chapter management and leadership development.

The conference will be held at MEET Las Vegas in downtown Las Vegas. Visit PAYO online to view the full conference agenda. The event is sponsored by Wisely by ADP.

PayrollOrg is the leader in payroll education, publications, and training. Visit PAYO online at www.payroll.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/payrollorgs-chapter-leadership-summit-to-equip-payroll-chapter-leaders-with-tools-for-success-302299403.html

SOURCE PayrollOrg

Continue Reading

Trending